Guided Therapeutics (GTHP) Current Deferred Revenue (2010 - 2025)
Guided Therapeutics (GTHP) reported Current Deferred Revenue of $189000.0 for Q4 2025, down 77.74% on a YoY basis from $849000.0 in Q4 2024, and down 72.58% sequentially from $689318.0 in Q3 2025.
Guided Therapeutics (GTHP) Current Deferred Revenue (2010 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 16 years of Current Deferred Revenue data on file, last reported at $189000.0 in Q4 2025.
- For the quarter ending Q4 2025, Current Deferred Revenue fell 77.74% year-over-year to $189000.0; the trailing twelve-month figure through Dec 2025 stood at $189000.0 (down 77.74% YoY), and the FY2025 full-year result was $189000.0, down 77.74% from the prior year.
- Current Deferred Revenue slipped to $189000.0 in Q4 2025, from $689318.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $514.0 million in Q1 2022 to a low of $62000.0 in Q1 2021.
- A 5-year average of $29.3 million and a median of $511050.5 in 2022 frame the typical range for Current Deferred Revenue.
- Across the five-year window, Current Deferred Revenue soared 828932.26% in 2022 and sank 99.91% in 2023, its largest moves.
- Tracing GTHP's Current Deferred Revenue over 5 years: stood at $337315.0 in 2021, then soared by 50.93% to $509101.0 in 2022, then decreased by 16.67% to $424225.0 in 2023, then jumped by 100.13% to $849000.0 in 2024, then slumped by 77.74% to $189000.0 in 2025.
- Business Quant data shows GTHP's Current Deferred Revenue at $189000.0 in Q4 2025, $689318.0 in Q3 2025, and $679000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 189,000.00 |
| Sep 30, 2025 | 689,318.00 |
| Jun 30, 2025 | 679,000.00 |
| Mar 31, 2025 | 670,000.00 |
| Dec 31, 2024 | 849,000.00 |
| Sep 30, 2024 | 748,000.00 |
| Jun 30, 2024 | 747,780.00 |
| Mar 31, 2024 | 748,000.00 |
| Dec 31, 2023 | 424,225.00 |
| Sep 30, 2023 | 450,516.00 |
| Jun 30, 2023 | 445,444.00 |
| Mar 31, 2023 | 487,882.00 |
| Dec 31, 2022 | 509,101.00 |
| Sep 30, 2022 | 509,101.00 |
| Jun 30, 2022 | 513,000.00 |
| Mar 31, 2022 | 514.00 Mn |
| Dec 31, 2021 | 337,315.00 |
| Sep 30, 2021 | 278,000.00 |
| Jun 30, 2021 | 62.00 Mn |
| Mar 31, 2021 | 62,000.00 |